Position in EXEL
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$23,069
-$3,737 QoQ
Shares Held
424
-32.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#641
of 756 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cassaday & Co Wealth Management LLC holds $483,213 across 25 Biotechnology names. EXEL ranks #7 (4.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
2,052 | $111,916 | |
| 2 | VKTX |
Viking Therapeutics, Inc.
|
2,174 | $84,807 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130 | $64,574 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
99 | $61,730 | |
| 5 | TECH |
BIO-TECHNE Corp
|
700 | $49,455 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
400 | $31,716 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
424 | $23,069 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
840 | $21,252 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23,069 | 424 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $26,806 | 625 | Shares | Sole | 2026-05-07 | |
| No filing history on record for this holder in this stock. | ||||||